Table 1.
Characteristics of patients who did and did not experience death or cardiovascular event.
| AllN = 41 | Death or CV EventN = 31 | No Death or CV EventN = 10 | p Value | |
|---|---|---|---|---|
| Patient characteristics | ||||
| Age at index, median (IQR) | 74 (67, 84) | 74 (64, 83) | 74 (68, 90) | 0.27 |
| Median time from MPN to index, months (IQR) | 47 (12, 84) | 32 (8, 75) | 82 (55, 107) | 0.029 |
| MedianfFollow-up, months (IQR) | 80 (27, 98) | 80 (27, 100) | 67 (13, 93) | 0.68 |
| BMI (IQR) | 23 (19, 26) | 23 (19, 27) | 23 (20, 26) | 0.22 |
| Male, N (%) | 26 (63) | 21 (68) | 5 (50) | 0.26 |
| MPN characteristics | ||||
| Age at MPN, median (IQR) | 68 (63, 79) | 71 (63, 79) | 68 (63, 81) | 0.95 |
| Type of MPN, N (%) | ||||
| PV | 15 (37) | 12 (39) | 3 (30) | 0.70 |
| ET | 19 (46) | 13 (42) | 6 (60) | |
| MF | 7 (17) | 6 (19) | 1 (10) | |
| JAK2V617F Positive, N (%) | 30 (73) | 26 (84) | 4 (40) | 0.013 |
| MPL Positive, N (%) | 1 (2.4) | 1 (3.2) | 0 | 1.00 |
| CALR Positive, N (%) | 3 (7.3) | 2 (6.4) | 1 (10.0) | 1.00 |
| Treatment for MPN, N (%) | 38 (93) | 29 (94) | 9 (90) | 1.00 |
| Hydroxyurea | 30 (73) | 22 (71) | 8 (80) | 0.70 |
| Ruxolitinib | 7 (17) | 3 (16) | 2 (20) | 1.00 |
| Phlebotomy | 13 (31.7) | 2 (20.0) | 11 (35.5) | 0.46 |
| Anagrelide | 4 (9.8) | 2 (20.0) | 2 (6.4) | 0.24 |
| Co-Morbidities, N (%) | ||||
| Prior CVD a | 24 (59) | 17 (55) | 7 (70) | 0.48 |
| CAD | 12 (29) | 9 (29) | 3 (30) | 1.00 |
| Prior bleed | 10 (24) | 7 (29) | 3 (18) | 0.48 |
| DM | 5 (12) | 4 (13) | 1 (10) | 1.00 |
| HTN | 31 (76) | 24 (77) | 7 (70) | 0.68 |
| Prior stroke/TIA | 8 (20) | 8 (26) | 0 | 0.16 |
| Atrial fibrillation | 12 (29) | 8 (26) | 4 (40) | 0.44 |
| HF | 15 (37) | 13 (42) | 2 (20) | 0.28 |
| Never smoking | 13 (32) | 11 (35) | 2 (20) | 0.46 |
| Medications 1 year post-index, N (%) | ||||
| Aspirin | 37 (90) | 28 (90) | 9 (90) | 1.00 |
| P2Y12 inhibitor | 19 (46) | 15 (48) | 4 (40) | 0.73 |
| DAPT | 19 (46) | 15 (48) | 4 (40) | 0.73 |
| Anticoagulation | 12 (29) | 10 (32) | 2 (20) | 0.69 |
| Statin | 30 (73) | 25 (81) | 5 (50) | 0.098 |
| Labs at index | ||||
| WBC (K/µL), median (IQR) | 11 (8, 20) | 14 (9, 25) | 8 (8, 11) | 0.008 |
| Hematocrit (%), median (IQR) | 39 (32, 42) | 41 (32, 43) | 38 (32, 41) | 0.53 |
| Platelets (K/µL), median (IQR) | 429 (311, 608) | 429 (266, 708) | 420 (347, 607) | 0.86 |
| Spleen size (cm), median (IQR) | 13 (11, 15) | 14 (12, 16) | 11 (8, 14) | 0.065 |
| Type of event | ||||
| STE-ACS | 2 (5) | 2 (6) | 0 | 1.00 |
| NSTE-ACS | 39 (95) | 29 (94) | 10 (100) | 1.00 |
| LVEF at index, median (IQR) | 58 (43, 68) | 55 (47, 70) | 60 (45, 68) | 0.98 |
| Treatment, N (%) | ||||
| PCI | 16 (39) | 13 (42) | 3 (30) | 0.71 |
| DES | 8 | 7 | 1 | N/A |
| BMS | 6 | 4 | 2 | N/A |
| POBA | 1 | 1 | 0 | N/A |
| Unknown | 1 | 1 | 0 | N/A |
| CABG | 7 (17) | 6 (19) | 1 (10) | 0.66 |
| Any revascularization | 23 (56) | 19 (61) | 4 (40) | 0.29 |
| Outcomes | ||||
| Acute coronary syndrome | 11 (27) | 11 (35) | 0 | N/A |
| Ischemic stroke | 6 (15) | 6 (19) | 0 | N/A |
| HF hospitalization | 17 (41) | 17 (55) | 0 | N/A |
| All-cause death | 17 (41) | 17 (55) | 0 | N/A |
| CV-related death | 8 (20) | 8 (26) | 0 | N/A |
Abbreviations: ACS, acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DM, diabetes mellitus; ET, essential thrombocytosis; HF, heart failure; HTN, hypertension; IQR, interquartile range; LVEF, left ventricular ejection fraction; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MRA, mineralocorticoid antagonist; NSTE-ACS, non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; POBA, plain old balloon angioplasty; PV, polycythemia vera; STE-ACS, ST-elevation acute coronary syndrome; TIA, transient ischemic attack; WBC, white blood cell count. a Prior CVD includes prior CAD, peripheral vascular disease, heart failure, stroke or atrial fibrillation.